Your browser doesn't support javascript.
loading
Scientific and Regulatory Policy Committee Points to Consider: Primary Digital Histopathology Evaluation and Peer Review for Good Laboratory Practice (GLP) Nonclinical Toxicology Studies.
Forest, Thomas; Aeffner, Famke; Bangari, Dinesh S; Bawa, Bhupinder; Carter, Jonathan; Fikes, James; High, Wanda; Hayashi, Shim-Mo; Jacobsen, Matthew; McKinney, LuAnn; Rudmann, Daniel; Steinbach, Thomas; Schumacher, Vanessa; Turner, Oliver; Ward, Jerrold M; Willson, Cynthia J.
Afiliação
  • Forest T; Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Aeffner F; Amgen, Inc., South San Francisco, California, USA.
  • Bangari DS; Sanofi R&D, Framingham, Massachusetts, USA.
  • Bawa B; AbbVie, Inc., North Chicago, Illinois, USA.
  • Carter J; Labcorp Early Development Laboratories Ltd, Harrogate, UK.
  • Fikes J; Biogen, Inc., Cambridge, Massachusetts, USA.
  • High W; High Preclinical Pathology Consulting, Rochester, New York, USA.
  • Hayashi SM; Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan.
  • Jacobsen M; Division of Food Additives, National Institute of Health Sciences, Kawasaki, Kanagawa, Japan.
  • McKinney L; Regulatory Safety Centre of Excellence, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Rudmann D; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Steinbach T; Charles River Laboratories International, Inc., Wilmington, Massachusetts, USA.
  • Schumacher V; Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina, USA.
  • Turner O; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
  • Ward JM; Novartis, East Hanover, New Jersey, USA.
  • Willson CJ; GlobalVetPathology, Montgomery Village, Maryland, USA.
Toxicol Pathol ; 50(4): 531-543, 2022 06.
Article em En | MEDLINE | ID: mdl-35657014
ABSTRACT
The Society of Toxicologic Pathology's Scientific and Regulatory Policy Committee formed a working group to consider the present and future use of digital pathology in toxicologic pathology in general and specifically its use in primary evaluation and peer review in Good Laboratory Practice (GLP) environments. Digital histopathology systems can save costs by reducing travel, enhancing organizational flexibility, decreasing slide handling, improving collaboration, increasing access to historical images, and improving quality and efficiency through integration with laboratory information management systems. However, the resources to implement and operate a digital pathology system can be significant. Given the magnitude and risks involved in the decision to adopt digital histopathology, this working group used pertinent previously published survey results and its members' expertise to create a Points-to-Consider article to assist organizations with building and implementing digital pathology workflows. With the aim of providing a comprehensive perspective, the current publication summarizes aspects of digital whole-slide imaging relevant to nonclinical histopathology evaluations, and then presents points to consider applicable to both primary digital histopathology evaluation and digital peer review in GLP toxicology studies. The Supplemental Appendices provide additional tabulated resources.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Revisão por Pares / Toxicologia Tipo de estudo: Evaluation_studies / Prognostic_studies Idioma: En Revista: Toxicol Pathol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Revisão por Pares / Toxicologia Tipo de estudo: Evaluation_studies / Prognostic_studies Idioma: En Revista: Toxicol Pathol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos